Home  |  Terms and Conditions  |  Privacy Policy  |  Sitemap    Cookies

© Raeside Web Design

  + 44 (0) 1295 660117


Home About Us Products References Ordering Codes R & D News Contact Us

New book

Smoking – what all healthcare professionals need to know by Dr. Graham F. Cope

Available from www.mkupdate.co.uk


Back to top

27 October 2017


A new exhibition at the Science Museum, London will feature an invention from the Oxford area which could revolutionise the diagnosis of ‘Superbugs’

The exhibition entitled ‘Superbugs: the Fight for Our Lives’ will open on the 9th November 2017 and run until Spring 2019. It will ‘explore how society is responding to the enormous challenge of antibiotic resistance, and will feature scientific research from across the globe and the personal stories of those waging war on the superbugs’.

Dame Sally Davies, the Chief Medical Officer recently said that ‘If antibiotics lose their effectiveness it would spell “the end of modern medicine”’. She is "really worried that without effective antibiotics, common medical procedures such as surgery and cancer treatments could become too risky”.

Part of the exhibition will include an invention from GFC Diagnostics Ltd, a company based in Chipping Warden, Oxfordshire. Using a unique testing device invented at the University of Birmingham the company has developed a cheap, quick and simple test which can be used to detect the ‘superbug’ MRSA which grows on the skin and is a ‘hospital acquired infection’.  

The test called MicroScreen is soon to undergo clinical trials and can be used in the case of emergency operations when saving time is very important. Currently prior to an operation mouth and skin swabs are sent to the lab to screen for the infection. This can take up to three days.

“Our test takes about thirty minutes and does not need expensive equipment or highly trained staff” says Bruce Savage, CEO of GFC Diagnostics “This test could be a major step forward to speed up the diagnosis of these harmful bacteria and so reduce the harm caused by drug resistant bacteria. The rapid diagnosis will allow the right antibiotics to be used, instead of using the broad-spectrum antibiotics’.

Work is underway to develop a similar test for the ‘nightmare’ ‘superbug’ CPE which as been described as ‘Almost untreatable’ and poses a serious threat to patients.

Dr. Graham Cope, Technical Director said “New diagnostic tests for ‘superbugs’ are being developed all across the globe but our test has the advantage that it does not require any complex, expensive equipment or highly trained staff and it can be carried out by a nurse in a room off the operating theatre in a matter of minutes”.

GFC Diagnostics has already received a Discovery Award as part of the Longitude Prize. The money has been used to develop the test which will be considered for the £8m prize whose aim is to ‘Achieve the ultimate goal of a novel, affordable and rapid point-of-care test that could be used anywhere in the world to determine when antibiotics should be used’.

GFC Diagnostics

The test, called MicroScreen, detects the genes inside the antibiotic resistant bacteria and is a major breakthrough in the battle against drug resistant infection, now widely regarded as a ticking time-bomb.  Chief Medical Office, Professor Dame Sally Davies has said: “Antimicrobial resistance poses a catastrophic threat” adding that “antibiotic resistance represents a threat that may be "as important as climate change for the world".

MicroScreen presents a cheap, quick and simple test which can be used on pre-operative patients in hospital to establish if they carry antiobitic restistant bacteria, including MRSA, to to avoid uneccesssary use of antiobiotics and ensure they receive appropriate treatment for their own recovery and the well-being of other patients. .To date other tests available are complex, need to use expensive equipment and take around three days for the results to be made available

GFC Diagnostics Wins Global Award for Development of Cheap, Quick and Simple MRSA Test

GFC Diagnostics has been awarded one of the three Longitude Prize Discovery Awards awarded to UK organisations for the company’s ground-breaking development of a test which successfully detects antibiotic resistant bacteria, including the superbug MRSA, within 30 minutes.

The GFC team, from left: chief executive Bruce Savage, technical director Dr Graham Cope, senior scientist Dr Graham Mock and scientist Alex Savage.

A FIRM based near Banbury has scooped a Longitude Prize Discovery award for developing a test for superbugs.

GFC Diagnostics’ MicroScreen detects antibiotic-resistant bacteria, such as MRSA, in 30 minutes compared to existing tests which take three days.

The new method is also cheaper, as it does not need expensive equipment or highly trained staff.

Chief executive Bruce Savage explained: “This could be a major step forward to reduce the harm caused by drug-resistant bacteria.

“This rapid test will give a quick diagnosis and prevent the unnecessary use of broad spectrum antibiotics.

“It will reduce healthcare costs by helping to stop the spread of deadly infections throughout a hospital.”

GFC Diagnostics Team

Test to seek superbugs wins top prize

30th November 2016


Bicester Advertiser





05 June 2018

Medical diagnostics company awarded £9,000 grant to support the development of a new product.

Chipping Warden based medical diagnostics company GFC Diagnostics is aiming for further growth after securing a £9,000 grant from the Innovate Northamptonshire project to help finance the development of a rapid test for the detection of a group of bacteria - Carbapenemase Producing Enterobacteriacea (CPE).

The funding will allow the company to work alongside the University of Northampton to develop a rapid test using new technology that could be automated and produce a result in a few hours. This will simplify the CPE detection process that at the moment takes 3 to 4 days and is very labour intensive.

CPE are a common group of bacteria that have started to become resistant to antibiotics that are used to treat patients with very severe infections. If the bacteria become resistant to these antibiotics, then it is difficult to treat the patients and many die. The provision of a rapid automated assay to clinical microbiology laboratories will reduce their expenditure and will free up staff to perform other tests. The test should also reduce costs in the NHS since using this test will mean that it is quicker and easier to diagnose these bacteria.

Bruce Savage of GFC Diagnostics said:The growth of antibiotic resistance is of huge concern globally. The danger is one of the greatest that humanity has faced in recent times. In a drug-resistant world, many aspects of modern medicine would simply become impossible. This project will demonstrate that the GFC Diagnostics company is capable of working on much more complex antibiotic resistant bacteria and the outcome from the project will help towards development of other products”.

Aurel Nastase, the Growth Hub’s Innovation Adviser, added:

“Innovation is a vital tool for today’s businesses if they want to become sustainable and grow in this rapidly changing world. Our Innovate Northamptonshire project is all about encouraging businesses to explore different ways of working, generating new ideas and ultimately developing new products.”

The Innovate Northamptonshire project is part-funded by the European Regional Development Fund and delivered by Northamptonshire Growth Hub, a partnership between The University of Northampton and Northamptonshire County Council.

In addition to adviser and funding support, the project also offers a combination of workshops – please see our events section for more information.

 To find out more about GFC Diagnostics visit www.gfcdiagnostics.com